Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly

Benzinga

2023-02-07

Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate.
In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002.
The therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).
According to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.
Dragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline.
Last month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.
The announcement marks the first TriNKET opt-in outside of oncology.
Dragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.
Price Action: BMY shares are down 0.18% at $74.32 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2309144293"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2309144293\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2309144293?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/whZOZUxwYGUfMx_S4MwEUQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3","is_english":true,"pubTime":"2023-02-07 01:41","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2309144293","market":"us","top_or_hot":-1,"title":"Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/t_72852E2HLObeNLK1rBZA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Bristol-Myers</strong> <strong>Squibb &amp; Co</strong> (NYSE: BMY) has returned the exclusive rights to <strong>Dragonfly Therapeutics</strong>' IL-12 oncology candidate.</li>\n<li>In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002. </li>\n<li>The therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).</li>\n<li>According to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.</li>\n<li>Dragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline. </li>\n<li>Last month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.</li>\n<li>The announcement marks the first TriNKET opt-in outside of oncology.</li>\n<li>Dragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.</li>\n<li><strong>Price Action:</strong> BMY shares are down 0.18% at $74.32 on the last check Monday.</li>\n</ul>\n<p>Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.</p>\n<p>This article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com</p>.\n<p><i>© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2023-02-07 01:41</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/t_72852E2HLObeNLK1rBZA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Bristol-Myers</strong> <strong>Squibb &amp; Co</strong> (NYSE: BMY) has returned the exclusive rights to <strong>Dragonfly Therapeutics</strong>' IL-12 oncology candidate.</li>\n<li>In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002. </li>\n<li>The therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).</li>\n<li>According to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.</li>\n<li>Dragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline. </li>\n<li>Last month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.</li>\n<li>The announcement marks the first TriNKET opt-in outside of oncology.</li>\n<li>Dragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.</li>\n<li><strong>Price Action:</strong> BMY shares are down 0.18% at $74.32 on the last check Monday.</li>\n</ul>\n<p>Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.</p>\n<p>This article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com</p>.\n<p><i>© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/big-pharma-bristol-myers-returns-174114403.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/big-pharma-bristol-myers-returns-174114403.html","article_id":"2309144293","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/whZOZUxwYGUfMx_S4MwEUQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2309144293","pubTimestamp":1675705274,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' I","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"大型制药公司百时美施贵宝将价值4.75亿美元的IL-12肿瘤学资产返还给蜻蜓","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"IL":1,"MYE":1},"content_text":"Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate.\nIn 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002. \nThe therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).\nAccording to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.\nDragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline. \nLast month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.\nThe announcement marks the first TriNKET opt-in outside of oncology.\nDragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.\nPrice Action: BMY shares are down 0.18% at $74.32 on the last check Monday.\n\nDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.\nThis article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com.\n© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}